SSA
PTGX icon

Schonfeld Strategic Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
+28,072
New +$2.93M 0.01% 793
2025
Q4 		– Sell
-95,190
Closed -$6.32M – 2490
2025
Q3 		$6.32M Buy
95,190
+18,122
+24% +$1.03M 0.04% 505
2025
Q2 		$4.26M Sell
77,068
-210,233
-73% -$10.1M 0.03% 617
2025
Q1 		$13.9M Buy
+287,301
New +$12M 0.08% 237
2024
Q4 		– Sell
-61,026
Closed -$2.75M – 2314
2024
Q3 		$2.75M Buy
61,026
+11,962
+24% +$483K 0.02% 757
2024
Q2 		$1.7M Buy
+49,064
New +$1.44M 0.01% 975
2024
Q1 		– Sell
-89,113
Closed -$2.04M – 2333
2023
Q4 		$2.04M Sell
89,113
-64,985
-42% -$1.14M 0.01% 790
2023
Q3 		$2.57M Buy
+154,098
New +$2.99M 0.02% 744
2023
Q2 		– Sell
-148,992
Closed -$3.43M – 2432
2023
Q1 		$3.43M Buy
+148,992
New +$2.5M 0.03% 543
2022
Q4 		– Sell
-31,814
Closed -$268K – 2927
2022
Q3 		$268K Sell
31,814
-16,218
-34% -$153K ﹤0.01% 2156
2022
Q2 		$380K Buy
48,032
+34,332
+251% +$415K ﹤0.01% 1527
2022
Q1 		$325K Buy
+13,700
New +$386K ﹤0.01% 1645
2021
Q3 		– Sell
-5,000
Closed -$224K – 2406
2021
Q2 		$224K Buy
+5,000
New +$165K ﹤0.01% 1613
2019
Q3 		– Sell
-101,800
Closed -$1.23M – 1194
2019
Q2 		$1.23M Buy
101,800
+77,800
+324% +$860K 0.04% 390
2019
Q1 		$301K Buy
+24,000
New +$212K 0.01% 833

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Schonfeld Strategic Advisors's PTGX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 28,072 shares worth $3.44M. The stake represents 0.01% of the portfolio and ranks #793 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in PTGX as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in PTGX in Q1 2019 and has held it in 15 quarters since. The position peaked at $13.9M in Q1 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Schonfeld Strategic Advisors held 28,072 shares of Protagonist Therapeutics worth $3.44M as of Q2 2026.
  • Protagonist Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #793 holding.
  • Schonfeld Strategic Advisors first reported a position in Protagonist Therapeutics in Q1 2019 and has held it in 15 quarters since.
  • Schonfeld Strategic Advisors's Protagonist Therapeutics position peaked at $13.9M in Q1 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.